Citigroup Maintains Buy on Zymeworks, Raises Price Target to $38
Citigroup analyst Yigal Nochomovitz maintains Zymeworks (NASDAQ:ZYME) with a Buy and raises the price target from $37 to $38.
Read original at benzingaStocks · News reference
Zymeworks Q2 EPS $(0.62) Misses $(0.41) Estimate, Sales $4.590M Miss $18.011M Estimate
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 8:07 PM
- Checked
- Aug 6, 2026, 8:07 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Zymeworks shares are trading higher after HC Wainwright & Co maintained its Buy rating on the stock and raised the price target from $51 to $55. Also, Citizens reiterated its Market Outperform rating and maintained a $32 price target.
Read original at benzingaAbercrombie & Fitch Posts Upbeat Q2 Results, Joins Semtech, Summit Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed, Nasdaq up 0.1%. Abercrombie & Fitch shares surge 31.6% after beating earnings and raising forecasts. Other top gainers include Kanzhun, Capricor Therapeutics, Semtech Corp, and more.
Read original at benzingaMongoDB To Rally Around 14%? Here Are 10 Top Analyst Forecasts For Wednesday
Top analysts changed outlook on top names: Piper raised $INTU price target, Ascendiant raised $QUBT target, BTIG cut $DKS target, HC raised $ZYME target, Needham increased $JAZZ target, Bernstein cut $MSTR target, Barclays raised $MDB target, UBS raised $SMTC target.
Read original at benzinga